Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients
- PMID: 19956444
- PMCID: PMC2779125
- DOI: 10.2147/ppa.s2300
Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients
Abstract
Background: This study compared effectiveness and acceptance of orally disintegrating olanzapine tablets (ODT) with standard-coated tablets (SOT) in acutely ill psychiatric patients admitted to psychiatric hospitals for emergency treatment.
Methods: Large, prospective, observational study at hospital emergency units across Germany in patients with a diagnosis or tentative diagnosis of acute schizophrenia treated with ODT or SOT. Clinical (CGI-S and CGI-I) outcomes, attitudes towards medication (Nursing Assessment of Medication Acceptance, NAMA) scale, suicidal ideation, and adverse events were assessed at start of treatment and after 2 weeks.
Results: Both olanzapine formulations, ODT (N = 247) and SOT (N = 207), showed similar effectiveness after 2 weeks. CGI-I improved in 92.1% of patients (ODT: 91.8%, SOT: 92.3%). In patients receiving both formulations suicidal ideations were reduced (ODT from 53.9% to 20.6%, SOT from 51.2% to 22.7%). ODT was preferably given to severely ill (SOT: 49.8%, ODT: 64.4%) and aggressive patients. Adverse events were reported for 6.5% of ODT- and 2.9% of SOT-patients. This difference was possibly caused by the characteristics of patients receiving ODT.
Conclusions: This non-randomized, observational study shows comparable outcomes and tolerability in patients treated with both olanzapine formulations. In an acute treatment setting, orally disintegrating tablets were preferably used for more severely ill and aggressive patients with low medication acceptance.
Keywords: acute treatment; observational study; olanzapine; schizophrenia.
Figures



Similar articles
-
Olanzapine orally disintegrating tablet: a review of efficacy and compliance.CNS Neurosci Ther. 2008 Fall;14(3):203-14. doi: 10.1111/j.1755-5949.2008.00053.x. CNS Neurosci Ther. 2008. PMID: 18801113 Free PMC article. Review.
-
Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.J Med Econ. 2012;15(3):531-47. doi: 10.3111/13696998.2012.662923. Epub 2012 Feb 21. J Med Econ. 2012. PMID: 22304338
-
An economic model to understand the cost-effectiveness of olanzapine orally dispersible tablets (ODT) and olanzapine film coated tablets as a group compared with other oral atypical antipsychotics for treating schizophrenia in Morocco.Ann Gen Psychiatry. 2024 Sep 18;23(1):33. doi: 10.1186/s12991-024-00516-y. Ann Gen Psychiatry. 2024. PMID: 39294740 Free PMC article.
-
Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.Expert Rev Pharmacoecon Outcomes Res. 2020 Oct;20(5):549-557. doi: 10.1080/14737167.2020.1807331. Epub 2020 Sep 23. Expert Rev Pharmacoecon Outcomes Res. 2020. PMID: 32757968
-
[Pharmaceutical formulations and adherence to pharmacological treatment in psychiatry: the example of oral disintegrating tablet of olanzapine].Riv Psichiatr. 2012 Jan-Feb;47(1):30-9. doi: 10.1708/1034.11289. Riv Psichiatr. 2012. PMID: 22358215 Review. Italian.
Cited by
-
Olanzapine orally disintegrating tablet: a review of efficacy and compliance.CNS Neurosci Ther. 2008 Fall;14(3):203-14. doi: 10.1111/j.1755-5949.2008.00053.x. CNS Neurosci Ther. 2008. PMID: 18801113 Free PMC article. Review.
-
Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder.Patient Prefer Adherence. 2017 Jun 6;11:1019-1025. doi: 10.2147/PPA.S124581. eCollection 2017. Patient Prefer Adherence. 2017. PMID: 28652711 Free PMC article.
-
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study.World J Biol Psychiatry. 2010 Oct;11(7):894-903. doi: 10.3109/15622975.2010.505663. World J Biol Psychiatry. 2010. PMID: 20653494 Free PMC article. Clinical Trial.
-
The Nursing Assessment of Medication Acceptance: the reliability and validity of a schizophrenia medication adherence scale.Ther Adv Psychopharmacol. 2017 Jan;7(1):11-16. doi: 10.1177/2045125316672546. Epub 2016 Oct 6. Ther Adv Psychopharmacol. 2017. PMID: 28101319 Free PMC article.
-
Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties.Patient Prefer Adherence. 2012;6:109-25. doi: 10.2147/PPA.S27344. Epub 2012 Feb 1. Patient Prefer Adherence. 2012. PMID: 22346347 Free PMC article.
References
-
- Alvarez E, Bobes J, Gomez J-C, et al. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. Eur Neuropsychopharmacol. 2003;13:39–48. - PubMed
-
- Baker RW, Kinon BJ, Maguire GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol. 2003;23:342–8. - PubMed
-
- Beasley CM, Sayler ME, Kiesler GM. The influence of pharmaco-therapy on self-directed and externally-directed aggression in schizophrenia. Schizophr Res. 1998;29:28.
-
- Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertaline: a prospective onset of action study. J Clin Psychopharmacol. 2003;23:358–64. - PubMed
-
- Bergstrom RF, Mitchell M, Witcher J, et al. Rapid onset of absorption with olanzapine orally disintegrating tablets. Schizophr Res. 2004;67:160.
LinkOut - more resources
Full Text Sources